Pelthos Therapeutics Inc. — Form SCHEDULE 13D/A
Filed November 3, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 38/100
What the filing says
Ligand Pharmaceuticals Inc. (filer) has amended its Schedule 13D disclosure regarding beneficial ownership in Pelthos Therapeutics Inc. (subject company). The filing is dated November 3, 2026, and includes four exhibits. The specific details of the amended ownership stake, dollar amounts, share counts, and the exact nature of the change are not disclosed in the header document provided—the substantive amendments appear to be contained in the referenced exhibits (EX-99.20 through EX-99.25), which are PDF attachments not reproduced in this text extract.
Why this rating
Schedule 13D amendments are routine disclosure updates when a >5% stakeholder's holdings change. Without exhibit details showing material ownership shift, this appears standard; Ligand is likely a known investor in micro-cap Pelthos ($6.7M). Insufficient data to assess whether amendment reflects significant stake concentration or dilution.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.